生物试剂
>
生化试剂
>
信号通路
> OR-1896
加入收藏 取消收藏

OR-1896  ≥98%

促销价¥{{model.attbuying.price}}

市场价¥0.00

累计销量0 累计评价0 人评论

别称 {{model.alias}}
中文名称 {{model.name}}
英文名称 {{model.enname}}
品牌 {{model.brand}}
CAS {{model.cas}}
分子式
分子量 {{model.molecularweight}}
MDL {{model.mdl}}
货号 {{model.procode}}
数量

+ -

件 库存{{model.attbuying.number}}件
立即购买 加入购物车 下载说明书

看了又看
包装规格：5mg 10mg 25mg in glass bottle
溶解性：溶于DMSO（62.5 mg/mL 超声）
产品描述：基本信息 产品编号： O10212 产品名称： OR-1896 CAS: 220246-81-1   储存条件 粉末 -20℃ 四年     分子式： C13H15N3O2 溶于液体 -80℃ 6个月 分子量： 245.28 -20℃ 1个月 化学名：  (R)-N-ACETYL-6-(4-AMINOPHENYL)-4,5-DIHYDRO-5-METHYL-3(2H)-PYRIDAZINONE Solubility (25°C)：   体外:   DMSO   Ethanol   Water   体内(现配现用):   ＜1mg/ml表示微溶或不溶。 普西唐提供的所有化合物浓度为内部测试所得，实际溶液度可能与公布值有所偏差，属于正常的批间细微差异现象。 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；⼀旦配成溶液，请分装保存，避免反复冻融造成的产品失效。   制备储备液   浓度   溶液体积 质量   1mg   5mg   10mg 1mM 4.0770mL 20.3849mL 40.7697mL 5mM 0.8154mL 4.0770mL 8.1539mL 10mM 0.4077mL 2.0385mL 4.0770mL   生物活性 产品描述 一种高选择性磷酸二酯酶(PDE III)抑制剂，是一种功能强大的血管扩张剂。OR-1896可以打开ATP敏感的K+通道，并具有Ca2+致敏作用。 靶点 PDE3/PDE Ⅲ K+ Channel Drug Metabolite   体外研究 There are many evidences has accumulated and revealed a variety of beneficial pleiotropic effects OR-1896.OR-1896 evokes prominent vasodilatory responses,activation of ATP-sensitive sarcolemmal K+channels of smooth muscle cells appears as a powerful vasodilator mechanism.Additionally,activation of ATP-sensitive K+channels in the mitochondria potentially extends the range of cellular actions towards the modulation of mitochondrial ATP production and implicates a pharmacological mechanism for cardioprotection. 体内研究 During the metabolism of Levosimendan approximately 5% of the drug is converted to the metabolite OR-1855 in the large intestine,and then acetylated in the liver to form the active metabolite OR-1896.Binding to plasma proteins is 98% for Levosimendan but only 40% for OR-1896.Unlike Levosimendan,which has an elimination half-life of 1-1.5h,the half-life of OR-1896 is about 75 to 80h allowing cardiovascular effects to persist up to 7 to 9 days after discontinuation of a 24-hour infusion of levosimendan.The pharmacokinetic of the parent drug is unaltered in subjects with severe renal impairment or with moderate hepatic impairment,whereas the elimination of its metabolites (OR-1896) can be prolonged.
保存条件：-20℃

猜你喜欢